Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

7.95
-0.1000-1.24%
Pre-market: 7.91-0.0400-0.50%05:37 EDT
Volume:6.88M
Turnover:54.59M
Market Cap:8.43B
PE:-8.04
High:8.02
Open:7.88
Low:7.84
Close:8.05
52wk High:12.43
52wk Low:1.95
Shares:1.06B
Float Shares:407.00M
Volume Ratio:0.73
T/O Rate:1.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9887
EPS(LYR):-0.3820
ROE:78.05%
ROA:-30.54%
PB:-8.05
PE(LYR):-20.81

Loading ...

Movement Alert|ImmunityBio Falls 5.17% in Regular Trading, Biotech Sector Profit-Taking Triggers Broad Pullback

Market Focus
·
Jul 14

Movement Alert|ImmunityBio Intraday Decline 5.58% in Regular Trading, Trading at $8.34

Market Focus
·
Jul 10

Movement Alert|ImmunityBio Falls 5.05% in Regular Trading, Trading at $8.475

Market Focus
·
Jul 07

Immunitybio Director Christobel Selecky Disposes of 159,478 Common Shares Worth $1.44 Million

Reuters
·
Jul 07

Movement Alert|ImmunityBio Falls 5.16% in Regular Trading, Trading at $8.685

Market Focus
·
Jul 06

Immunitybio Director Christobel Selecky Disposes of 96,722 Common Shares Worth $870,677.29

Reuters
·
Jul 02

Immunitybio Director Barry J. Simon Disposes of 25,000 Common Shares Worth $196,907.50

Reuters
·
Jun 27

Movement Alert|ImmunityBio Rises 5.65% in Regular Trading, Rebounds After Digesting FDA Warning Letter Pressure

Market Focus
·
Jun 17

Movement Alert|ImmunityBio Falls 5.12% in Regular Trading, FDA Warning Letter Continues to Suppress Market Confidence

Market Focus
·
Jun 17

ImmunityBio shareholders re-elect nine directors at annual meeting

Reuters
·
Jun 11

3 Growth Companies With High Insider Ownership Seeing Up To 94% Earnings Growth

Simply Wall St.
·
Jun 09

Movement Alert|ImmunityBio Rises 5.06% in Regular Trading, ASCO Clinical Data and Guideline Inclusion Fuel Rebound

Market Focus
·
Jun 09

ImmunityBio director Barry J. Simon sells 23,033 common shares worth $165,284

Reuters
·
Jun 06

Movement Alert|ImmunityBio Falls 5.01% in Regular Trading, Sustained Profit-Taking Pressure After Multiple Catalysts Realized

Market Focus
·
Jun 06

ImmunityBio (IBRX) Is Down 5.6% After New Phase 3 ANKTIVA Lung Cancer Data Release – Has The Bull Case Changed?

Simply Wall St.
·
Jun 05

ImmunityBio Advances HPV-Positive Head and Neck Cancer Trial, Setting Up a New Catalyst for IBRX Investors

TIPRANKS
·
Jun 05

ImmunityBio Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 02

ImmunityBio presents Phase 3 lung cancer data on ANKTIVA-based regimen at ASCO 2026

Reuters
·
Jun 02

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 01

Movement Alert|ImmunityBio Falls 5.12% in Regular Trading, Technical Rebound Fades as Profit-Taking Resumes After Multiple Catalysts Priced In

Market Focus
·
May 29